Investor Conference 2023

科妍生物科技股份有限公司
SciVision Biotech Inc.

Dr. Chun Chang Chen

Disclaimer

This slide contains our business prospect, financial condition and sales prognosis which are derived from our existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control.

The forward-looking statements in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.

Outline

1. Company & Product &Technology Overview

2. Business Operation

About SciVision Biotech Inc.

SciVision Biotech Inc.

- Established in 2001
- Listed on TSE in 2013 (Code: 1786)
- Professional high-class, pharmaceutical-grade Hyaluronic Acid medical device production
- Two factories are located at No. 1, S. 1st Rd., and No. 9, S. 6th Rd., Qianzhen Dist., Kaohsiung City, Taiwan
- Received certificates of QMS and ISO 13485 and complied with the regulations of the US FDA PIC/s GMP, etc.

Core Technologies

(Crosslinked Hyaluronic Acid Platform, CHAP®)



Intellectual Property Protection of CHAP



US009371402B2

(12) **United States Patent**
Chen et al.

(10) Patent No.: US 9,371,402 B2
(45) Date of Patent: Jun. 21, 2016

(54) METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

(75) Inventors: **Tor-Chern Chen**, Kaohsiung (TW); **Li-Su Chen**, Kaohsiung (TW)

(73) Assignee: **SCIVISION BIOTECH INC.**, K.E.P.Z. (TW)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 351 days.

(21) Appl. No.: **13/316,849**

(22) Filed: **Dec. 12, 2011**

(65) **Prior Publication Data**

US 2012/0095206 A1 Apr. 19, 2012

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/385,502, filed on Apr. 9, 2009, now abandoned.

(51) **Int. Cl.**
C08B 37/08 (2006.01)

(52) **U.S. Cl.**
CPC ***C08B 37/0072*** (2013.01)

(58) **Field of Classification Search**
CPC C08B 37/00; C08B 15/00; A61K 8/73; A61K 31/715
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

Tezel, A., & Fredrickson, G. H. (2008). The science of hyaluronic acid dermal fillers. Journal of Cosmetic and Laser Therapy, 10(1), 35-42.*

US 5,808,050, 9/1998, Mares-Guia (withdrawn).

Y. Tokita et al., Hydrolytic degradation of hyaluronic acid, Polymer Degradation and Stability, 1995, pp. 269-273, vol. 48.

Hans J.C.F. Nelis et al., A Sensitive Fluorimetric Procedure for the Determination of Aliphatic Epoxides under Physiological Conditions, Analytical Biochemistry, 1981, pp. 151-157, vol. 115.

European Search Report for 09004561.8-2115, which is a corresponding application, that cites US2002/049281, and U.S. Pat. No. 4,716,154, EP 1818344, US 2006/246137, EP 0070080, Jinghua et al., Characteristics of hyaluronic acid, polyethylene glycol of low and Tomihata K. et al., Preparation of films of low water content, vol. 18, No. 3.

European Office Action for corresponding European application.

Chinese Office Action dated which is a corresponding 10124290, and US 2007/

Chinese Office Action dated is a corresponding Chinese

Jinghua et al., Characteristics cross-linked by polyethylene Medical Colleges of PLA, vol. 23, No. 1.

Tomihata K. et al., Preparation of low water content. Biom 18, No. 3.

Office Action issued on Oct. application No. 2009-2191 JP H07-102002, and JP H

English abstract of Office corresponding JP patent ap



發明專利說明書 公告本

（本說明書格式、順序及粗體字，請勿任意更動，※記號部分請勿填寫）

※ 申請案號： 97136520 C08J 3/24 (2006.01)

※ 申請日期： 97.09.23 ※IPC 分類： ~~C08B~~ C08L 5/08 (2006.01)

一、發明名稱：（中文/英文）

交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申 請 人：（共 1 人）

姓名或名稱：（中文/英文）

科妍生物科技股份有限公司

SCIVISION BIOTECH INC.

代表人：（中文/英文）

韓開程

HAN, KAI-CHENG

住居所或營業所地址：（中文/英文）

高雄市806前鎮區高雄加工出口區南六路9號

9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

國 籍：（中文/英文）

中華民國 R.O.C.



(19) 中华人民共和国国家知识产权局

(12) 发明专利

(10)
(45)

(21) 申请号 200810172328.6

(22) 申请日 2008.10.31

审查员 张娜

(73) 专利权人 科妍生物科技股份有限公司
地址 中国台湾高雄市

(72) 发明人 陈拓成 陈丽凤

(74) 专利代理机构 北京律盟知识产权代理有限责任公司 11287
代理人 刘国伟

(51) Int. Cl.
C08J 3/24 (2006.01)
C08L 5/08 (2006.01)
C08K 5/1515 (2006.01)

(56) 对比文件
CN 101244290 A, 2008.08.20, 权利要求 1-5.
CN 1774272 A, 2006.05.17, 全文.
CN 101153061 A, 2008.04.02, 全文.
US 2007/0026070 A1, 2007.02.01, 权利要求 36-38.
CN 101244290 A, 2008.08.20, 权利要求

权利要求书 1 页 说明书 12 页

(54) 发明名称
交联透明质酸的制造方法

(57) 摘要
本发明涉及一种制造交联透明质酸的方法，其包含在约 10℃至约 30℃的低温下使包含透明质酸的溶液进行交联反应超过约 48 小时，本发明的方法不需纯化步骤即可降低交联剂的含量。

(19) Europäisches Patentamt / European Patent Office / Office européen des brevets

(11)

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
06.10.2010 Bulletin 2010/40

(51) Int Cl.:
C08B 37/00 (2006.01)

(21) Application number: 09004561.8

(22) Date of filing: 30.03.2009

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA RS

(71) Applicant: Scivision Biotech Inc.
Kaohsiung Export Processing Zone
Qianzhen D Kaohsiung (TW)

(72) Inventors:
• Chen, Tor-Chern
Pingtung City
Pingtung (TW)
• Chen, Li-Su
Nanzi Districht (T

(74) Representative: Hauck Patent- und Rechtsanwälte
Neuer Wall 50
20354 Hamburg (DE)

(54) Method for producing cross-linked hyaluronic acid

(57) A method for producing cross-linked hyaluronic acid comprising cross-linking one or more polymers at a low temperature from 10 to 30 °C for a reaction time greater than 48 hours under basic condition with a cross-linking agent to form a cross-linked hyaluronic acid, wherein the polymer is selected from the group consisting of hyaluronic acid, hyaluronate, derivatives thereof and a mixture thereof. Whereby, a cross-linking agent content in a product of the method is decreased so the product does not require purification.



(19) 日本国特許庁 (JP)

(12) 特 許 公 報 (B2)

(11) 特許番号
特許第5340093号
(P5340093)

(45) 発行日 平成25年11月13日 (2013.11.13)

(24) 登録日 平成25年8月16日 (2013.8.16)

(51) Int. Cl.
C08B 37/08 (2006.01)

F I
C08B 37/08 Z

請求項の数 19 外国特許出願 (全 20 頁)

(21) 出願番号 特願2009-219164 (P2009-219164)
(22) 出願日 平成21年9月24日 (2009.9.24)
(65) 公開番号 特開2010-77434 (P2010-77434A)
(43) 公開日 平成22年4月8日 (2010.4.8)
審査請求日 平成22年5月7日 (2010.5.7)
(31) 優先権主張番号 097136520
(32) 優先日 平成20年9月23日 (2008.9.23)
(33) 優先権主張国 台湾 (TW)

(73) 特許権者 509265450
科妍生物科技股▲分▼有限公司
台湾高雄市前鎮區高雄加工出口區南六路9號

(74) 代理人 100108453
弁理士 村山 靖彦

(74) 代理人 100064908
弁理士 志賀 正武

(74) 代理人 100089037
弁理士 渡邊 隆

(74) 代理人 100110364
弁理士 実広 信哉

(72) 発明者 陳拓成
台湾屏東市軟園里３鄰公園路１７４巷５號

(54) 【発明の名称】架橋ヒアルロン酸の製造方法

(57) 【特許請求の範囲】
【請求項１】
アルカリ条件において、セ氏１０～３０度の低温で、４８時間以上の反応時間をかけて１種類又は複数種類のポリマーと架橋剤とを架橋結合させることにより、架橋ヒアルロン酸を形成させるステップを有し、該ポリマーは、ヒアルロン酸、ヒアルロン酸塩、ヒアルロン酸とヒアルロン酸塩との混合物、ヒアルロン酸とヒドロキシ基を有する多糖類との混合物、及びヒアルロン酸塩とヒドロキシ基を有する多糖類との混合物からなる群より選択されるものであり、
前記低温で架橋結合を行うステップの前に、さらに、セ氏３５～６０度の高温で架橋結合反応を行うステップを有し、さらに、
ヒドロキシ基を有する前記多糖類が、カルボキシメチルセルロース（ＣＭＣ）、アルギン酸塩、コンドロイチン－４－サルフェート、コンドロイチン－６－サルフェート、キサンタンガム、キトサン、ペクチン、寒天、カラギーナン、グアールガムからなる群より選択されるものであることを特徴とする架橋ヒアルロン酸の製造方法。
【請求項２】
前記ヒアルロン酸塩がヒアルロン酸ナトリウム、ヒアルロン酸カリウム、ヒアルロン酸亜鉛からなる群より選択されるものであることを特徴とする請求項１に記載の架橋ヒアルロン酸の製造方法。
【請求項３】
前記アルカリ条件が０．０５～１．５Ｎ’であることを特徴とする請求項１に記載の架

10

20

United States

Taiwan

Japan

China

EU

Core Products of SciVision



Facial Aesthetics

Geriatrics care



Surgery



Urinary

Market research on global market value and growth rate

Applied field	Items	Global market value in 2022	CAGR
Facial Aesthetics	Dermal Filler	5.5 billion	10.5 %
Geriatrics Care	Synovial Fluid Supplement	3.9 billion	7.3 %
Surgery	Absorbable Adhesion Barrier	4.1 billion	9.8 %
Urinary	Intravesical Instillation	1.3 billion	5.2 %

1. Facial Aesthetics (Dermal Fillers), Global market insight
2. Hyaluronic Acid Viscosupplementation - Market Insights, Competitive Landscape, and Market Forecast - 2028
3. Increasing Awareness & Rising Adoption by Surgeons to Drive Growth in the Global Anti-Adhesion Products Market, According to New Report by Global Industry Analysts, Inc.
4. Global Interstitial Cystitis Drugs Market Report and Forecast 2023-2031

Classification of HA Dermal Filler

Gel type vs Particle type

Based on the gel type, HA facial dermal implant can be divided into monophasic type and biphasic type. The leading brand for each type is Juvederm from Allergan and Restylane from Galderma respectively.

monophasic(Gel type)
Allergan Juvederm

biphasic(Particle type)
Galderma Restylane

HA Dermal Filler

Monophasic Fillers (Gel type)

Product advantages

- ✓ High safety performance
- ✓ Smooth and natural
- ✓ Easy operation

Biphasic Fillers (Particle type)

Product advantages

- ✓ High safety performance
- ✓ Strong structural support
- ✓ Shift resistance
- ✓ Excellent viscoelasticity
- ✓ Sufficient active ingredients
- ✓ Good resistance to degradation

Benchmark Comparison















The texture of gel of ANiMERS is as smooth as that of Juvederm

Biphasic HA Fillers of SciVision are very supportive

Biphasic HA Fillers of SciVision

Traditional biphasic HA Fillers

Traditional Monophasic HA Fillers

Clinical Trials and Publications

1. A Guide to Cheek Augmentation: Single-Point Deep Injection of Hyaluronic Acid Filler at Midface in Close Proximity to Medial Suborbicularis Oculi Fat (SOOF) Area. Journal of Cosmetics, Dermatological Sciences and Applications. 2016 Jan 06(01):1-8.
2. Use of High-Resolution Ultrasound (HRU) in the Assessment of Deep Injections of CHAP-Hyaluronic Acid (CHAP-HA) Fillers for Midface Lift. Journal of Cosmetics, Dermatological Sciences and Applications. 2018 Jan 08(03):126-132.
3. Dual-Plane Injection Technique With Microscale Tumescent Solution for Asian Rhinoplasty. Dermatol Surg. 2021 Jul 1;47(7):1015-1016.
4. CHAP–hyaluronic acid (CHAP-HA) filler as an optimal candidate for forehead filler augmentation using a 3-point injection technique. Journal of Cosmetics, Dermatological Sciences and Applications. 2021 Jan 11(02):76-83.

Product injected around the eye was safe and effective, with high usage satisfaction

Figure 5. Before (upper) and immediately after (lower) single point deep injection of HA filler (1ml on each side) for cheek augmentation using 27 G sharp needle. Satisfactory results were noted with minimal bruising. Left: Case 2, Right: Case 7.

Product has good tissue compatibility



Figure 5. High-resolution ultrasound imaging immediately after HA injection (a, d, g, j), at 2-Week (d, e, h, k) and 4-week (c, f, i, l) follow up. Hydration of the HA would occur (arrows), and the ha would appear to be more heterogenous and hyperechoic (arrowheads) and may became completely unidentifiable with the surrounding tissues in the 4th week follow up (i, j).

Develop injection guidelines for high-risk areas



Guidelines for forehead augmentation





Future research and development direction

Collagen Stimulator



Absorbable polymeric materials such as **polymethyl methacrylate**, **short peptides**, **calcium hydroxyapatite**, **polylactic acid**, or **polycaprolactone** induce fibroblasts to synthesize collagen.
Implants of the polymeric materials will be developed in the future to expand the indications for stimulating collagen proliferation.

II. Synovial Fluid Supplement

1 injection for 12 months

1 injection for 6 months
Anti-free Radical Protection Type

1 injection for 6 months

3 injection for 6 months

Anti-free Radical Protection Type

JETKNEE Synovial Fluid Supplement

Product advantages

- ✓ 1 injection for 6 months
- ✓ Anti-free Radical Protection Type
- ✓ Free of animal origin
- ✓ Easy to operate

Degradation Test with ROS (H_2O_2)



JETKNEE, containing 2% HA with addition of Mannitol prolongs the protective effect of HA in the joints by removing free radicals.

SciVision Biotech Inc.

Synovial Fluid Supplement

Product category	Treatment description	Global CAGR of treatments	Products
1-injection regimen (Long-acting)	Effect could be lasted for more than half a year with administrating 1 syringe.	10.2%	 1 injection for 6 months  1 syringe per year Super Long-Acting Type  Anti-free Radical Protection Type
3-injection regimen	Effect could be lasted for half a year with administrating 3 syringes continuously , 1 syringe per week.	5.9%	 Best-selling product in Taiwan
5-injection regimen	Effect could be lasted for half a year with administrating 5 syringes continuously , 1 syringe per week.	5.5%	

Source: Hyaluronic Acid Viscosupplementation | Medtech 360 | Market Analysis | Global | 2019 , DRG

Clinical Trials and Publications

1. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. J Bone Joint Surg Am. 2011 Sep 21;93(18):1720-6.
2. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. Exp Gerontol. 2014 Apr;52:30-5.
3. Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. J Bone Joint Surg Am. 2017 Mar 15;99(6):462-471.
4. Origin and Efficacy of Hyaluronan Injections in Knee Osteoarthritis: Randomized, Double-Blind Trial. Med Sci Monit. 2018 Jul 9;24:4728-4737.
5. Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel cross-linked hyaluronic acid in the treatment of knee osteoarthritis. J Back Musculoskelet Rehabil. 2018;31(4):709-718.
6. Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study. BMC Musculoskelet Disord. 2021 Jun 23;22(1):572.
7. Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis. Sci Rep. 2021 Jan 8;11(1):140.
8. Efficacy of Intra-Articular Injection of Biofermentation-Derived High-Molecular Hyaluronic Acid in Knee Osteoarthritis: An Ultrasonographic Study. Cartilage. 2022 Jan-Mar;13(1):19476035221077404.
9. Single Injection of Cross-Linked Hyaluronate in Knee Osteoarthritis: A 52-Week Double-Blind Randomized Controlled Trial. Pharmaceutics. 2022 Aug 25;14(9):1783.

The pain relief effect is better than Sanofi's one-injection product



The thickness of the quadriceps and cartilage improved significantly at 3 and 6 months after surgery.



The effect can be maintained for more than one year, with high satisfaction.

Table 3 Patient satisfaction in time interval

Time	CHAP-HA ($N = 71$)	Linear-HA ($N = 69$)	P value
4th week	66.4 ± 22.4	68.4 ± 24.7	0.622
12th week	73.2 ± 23.4	71.1 ± 25.2	0.601
26th week	73.4 ± 22.7	63.5 ± 26.5	< 0.018‡
39th week	72.3 ± 22.4	52.1 ± 23.2	< 0.001‡
52th week	61.7 ± 22.0	37.5 ± 23.1	< 0.001‡

‡ indicates a significant difference between groups ($P < 0.05$)

Future research and development direction

Drug-containing
Synovial Fluid Supplement

repair damaged cartilage

Quick anti-inflammatory pain relief

Strengthens body tissue protection
Prolong product efficacy

III. Absorbable Adhesion Barrier

Postsurgical adhesion

Injured organ or tissue → The fibrin acts like a glue to seal the injury → Adhesion formation

Inflammation ↑



Gynecologic surgery

Tendon, peripheral nerve, joint surgery

III. Absorbable Adhesion Barrier

For gynecological pelvic surgery

Product advantages

- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance

For ligament, peripheral nerve, joint surgery

Product advantages

- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance
- ✓ Long effective protection time

Clinical Trials and Publications

1. A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery. J Appl Biomater Funct Mater. Jan-Dec 2021;19.
2. Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomectomy in Women with Submucosal Myomas: A Prospective, Randomized, Controlled Trial. Life. 2020 May 15;10(5):67.
3. Efficacy of Applying Hyaluronic Acid Gels in the Primary Prevention of Intrauterine Adhesion after Hysteroscopic Myomectomy: A Meta-Analysis of Randomized Controlled Trials. Life. 2020 Nov 15;10(11):285.

Product could effectively avoid or slow down the occurrence of postoperative adhesions.



Product could effectively avoid or slow down the occurrence of postoperative adhesions and was significantly better than competing products.

	CHA-P Gel (n = 24)	CHA Gel (n = 23)	No (n = 23)	*p*-Value
Intrauterine Adhesion				
No	22 (91.7%) [a]	19 (82.6%) [a]	14 (60.9%)	0.031
Yes	2 (8.3%) [a]	4 (17.4%) [a]	9 (39.1%)	
Modified AFS Stage				
0	22 (91.7%) [b]	19 (82.6%) [b]	14 (60.9%)	
I (mild)	2 (8.3%) [b]	3 (13.0%) [b]	1 (4.3%)	0.014
II (moderate)	0 [b]	1 (4.3%) [b]	4 (17.4%)	
III (severe)	0 [b]	0 [b]	4 (17.4%)	

The data are presented as number (percentage). CHA-P (PROTAHERE absorbable adhesion barrier®, SciVision Biotech Inc., Kaohsiung, Taiwan); CHA gel (Hyalobarrier® gel, Baxter, Pisa, Italy). No: no anti-adhesive agent gel treatment. AFS: American Fertility Society. [a] and [b]: The comparison between the CHA-P gel and CHA gel ([a]: *p*-value = 0.352, [b]: *p*-value = 0.497).

IV. Intravesical Instillation



HYAURO Intravesical Instillation

Product Specification

PACKAGE：50 mL per vial
ACTIVE INGREDIENT: Sodium Hyaluronate 40mg

DESCRIPTION

The glycosaminoglycan (GAG) layer on the luminal surface of the bladder wall is the primary defense mechanism which can provide a protective barrier to against microorganisms, carcinogens, crystals and other agents present in the urine. HYAURO Intravesical Instillation has been developed to temporarily replenish the deficient GAG layer on the bladder epithelium.

INDICATION

The product is indicated for cystitis-associated GAG layer deficiency such as interstitial cystitis and cystitis caused by infection, trauma, urinary stones, urine retention, tumors and radiation.

Core Products of SciVision



Facial Aesthetics

Geriatrics care



Surgery



Urinary

Outline

1. Company & Product &Technology Overview

2. Business Operation

Profit & Loss-Consolidated

Profit & Loss-Consolidated

Unit:NT thousand dollars (except for EPS)	2023/01/01~2023/06/30 (Reviewed)		2022/01/01~2022/06/30 (Reviewed)		Annual growth rate
Revenue	303,644	100%	232,578	100%	30.6%
Cost of Goods Sold	(94,272)	-31%	(86,850)	-37%	8.5%
Gross Profit	209,372	69%	145,728	63%	43.7%
Operating Expense	(128,955)	-43%	(104,997)	-45%	22.8%
Operating Income	80,417	26%	40,731	18%	97.4%
Non-operating Income,Net	7,758	3%	39,134	16%	-80.2%
Income before Tax	88,175	29%	79,865	34%	10.4%
Net Income	83,970	28%	66,626	29%	26.0%
EPS(NT$)	1.26		1.01		

Domestic and International Sales Ratio

2023 Jan.~Jun. & 2022 Jan.~Jun.





Product Portfolio Sales Ratio

2023 Jan.~Jun. & 2022 Jan.~Jun.





Balance Sheet-Consolidated

Balance Sheet-Consolidated

Unit:NT thousand dollars

	2023/06/30 (Reviewed)		2022/06/30 (Reviewed)	
Cash and Cash Equivalents	680,975	31%	395,937	20%
Accounts Receivable	117,042	5%	78,835	4%
Inventories	95,165	4%	85,112	4%
Current Financial Assets at Fair Value through Profit or Loss	58,348	3%	-	0%
Amortized Cost Financial Assets	31,140	2%	120,948	6%
Property,Plant & Equipment	1,137,045	52%	1,185,303	59%
Other Current/Non-Current Assets	78,148	3%	149,727	7%
Total Assets	2,197,863	100%	2,015,862	100%
Current Liabilities	275,855	12%	212,268	10%
Long-Term & Other Liabilities	411,243	19%	380,894	19%
Total Liabilities	687,098	31%	593,162	29%
Total Shareholders' Equities	1,510,765	69%	1,422,700	71%
Key Indices				
A/R Turnover (Days)	62.31		61.68	
Inventory Turnover (Days)	184.91		176.52	
Current Ratio(x)	363.41%		335.19%	
Net Profit Margin(%)	27.65%		28.65%	

Cash Flows-Consolidated

Cash Flows-Consolidated

Unit:NT thousand dollars	2023/01/01~2023/06/30 (Reviewed)	2022/01/01~2022/06/30 (Reviewed)
From Operating Activities	99,324	69,164
Profit before tax	88,175	79,865
Depreciation & Amortisation	31,228	30,764
Net change in working capital	(20,079)	(41,465)
From Investing Activities	(4,754)	(26,862)
amortised cost	500	(80,150)
Capital expenditure	(8,400)	(3,217)
Net change in Investing item	3,146	56,505
From Financing Activities	(612)	(305,282)
Short-term loans	0	(304,523)
Net change in Fincncing item	(612)	(759)
Net Change in Cash	93,958	(262,980)
Beginning Balance	587,017	658,917
Ending Balance	680,975	395,937
Free Cash Flow	90,924	65,947

HEALTHY CASHFLOW AND EXPANDING PROFIT

Revenue



Gross and Operating Margin



Net Profit



Cash Generated From Operations Before Interest And Taxes



Our Vision

SciVision
BIOTECH INC.

Science Creates Better Visions